Table 3.
Comparison of baseline characteristics of the study population according to the presence of left abnormality.
| Demographic data | Without LA ABN (n = 38) | With LA ABN (n = 26) | P |
|---|---|---|---|
| Age (years) mean ± SD | 66.05 ± 6.2 | 68.46 ± 5.21 | 0.11 |
| Body mass index (kg/m2) | 29.26 ± 4.76 | 30.67 ± 3.77 | 0.21 |
| Body surface area (m2) | 1.81 ± 0.19 | 1.93 ± 0.16 | 0.008 |
| Sex: | |||
| Female | 14 (36.8%) | 10 (38.5%) | 0.9 |
| Clinical data: (n & % ) | |||
| Smoking | 18 (47.4%) | 8 (30.8%) | 0.18 |
| Hypertension | 34 (89.5%) | 20 (76.9%) | 0.17 |
| Diabetes | 6 (23.1%) | 12 (31.6%) | 0.46 |
| Previous stroke/TIA | 2 (7.7%) | 8 (21.1%) | 0.15 |
| Congestive heart failure | 20 (52.6%) | 14 (53.8%) | 0.92 |
| Vascular diseases | 12 (46.2%) | 22 (57.9%) | 0.36 |
| Pacemaker or ICD | 4 (10.5%) | 4 (15.4%) | 0.56 |
| CHADS2 | 1.77 ± 0.82 | 2.16 ± 1.1 | 0.003 |
| CHA2DS2-VASc | 3.46 ± 0.95 | 3.79 ± 1.34 | 0.002 |
| Laboratory data: mean ± SD | |||
| Hemoglobin (g/d) | 12.91 ± 1.54 | 13.25 ± 1.33 | 0.36 |
| Platelet (103/μL) | 241.79 ± 49.06 | 219.08 ± 53.8 | 0.09 |
| INR | 1.83 ± 0.62 | 1.49 ± 0.42 | 0.02 |
| GFR (ml/min/1.73 m2) | 64.37 ± 19.32 | 69.75 ± 14.29 | 0.26 |
| AF duration: (n & % ) | |||
| ⩽48 h | 12 (31.6%) | 3 (11.5%) | 1 |
| >48 h–1 week | 11 (28.9%) | 2 (7.7%) | 0.11 |
| >1 week–1 year | 9 (23.7%) | 8 (30.8%) | 0.01 |
| >1 year | 6 (15.8%) | 13 (50.0%) | 0.004 |
| Antithrombotic treatment: | |||
| Oral anticoagulation | 20 (52.6%) | 6 (23.1%) | 0.02 |
| Antiplatelet agent | 12 (31.6%) | 18 (69.2%) | 0.003 |
| Enoxaparine | 16 (42.1%) | 4 (15.4%) | 0.02 |